Weight-Loss Pharma & Devices: Moving Beyond the 'Blockbuster Drug' Race – Roundtable Session 10

In recent years, the weight loss sector has witnessed a booming landscape characterized by the dual surge in pharmaceuticals and medical devices. GLP-1 drugs have led the global market trend, with the worldwide market size surpassing $50 billion in 2024, while domestic companies have actively broken through via major business development (BD) deals. Meanwhile, Chinese innovative medical devices have achieved repeated breakthroughs, with combination drug-device products entering the market one after another. Technology licensing and joint development have become the mainstream models of collaboration.

Against this backdrop, the 10th edition of VCBeat’s “China Innovative Healthcare Asset Lounge” Deal Roundtable focuses on “The Trillion-Yuan Weight Loss Sector: Sustained Surge, From Single-Point Breakthroughs to Ecosystem Building.” It features in-depth dialogues with frontline participants from both industry and capital markets, providing actionable deal logic and forward-looking strategic insights for buy-side investors, and jointly charting the next course for the weight loss sector.

Currently, the annual sales of GLP-1 drugs, reaching tens of billions of dollars, vividly attest to the unprecedented fervor in the weight loss sector. However, the roundtable panelists unanimously agreed that the true industry transformation lies in a comprehensive elevation of the value logic.

Han Dong, Head of Business Development at HighTide PharmaceuticalsIt is pointed out that the current weight-loss sector exhibits a clear “dual-engine” landscape: on one hand, there is the consumer-oriented single-indication weight-loss track, which prioritizes the speed and magnitude of weight reduction, with efficacy thresholds continuously rising; on the other hand, there is the serious medical track focused on comprehensive management of cardiorenal-metabolic diseases, whose core value lies in improving obesity-related complications such as diabetes, kidney disease, and cardiovascular diseases, thereby pursuing comprehensive health benefits. HighTide’s strategic choice focuses on the latter, shifting its R&D priorities toward validating comprehensive metabolic benefits and directing its collaboration efforts toward exploring combination therapies with leading GLP-1 players, thus avoiding homogeneous red-ocean competition in terms of weight-loss magnitude.

Chen Linfeng, Director of Strategic Financing at Tangji MedicalI strongly agree with this view. For medical device companies, beyond regulatory market access, the key challenge lies in demonstrating their long-term value to both the market and investors. He emphasized that three core capabilities must be built: first,Continuously Generating High-Quality Clinical and Real-World Datathe capability to demonstrate long-term safety and metabolic improvement effects; second, to constructIntegrated Doctor-Patient Full-Process Digital Service System, to address the core pain point of patient adherence; third, to buildInnovative Commercialization Ecosystem, collaborating with payers, healthcare institutions, and health management platforms to systematically address the industry-wide challenge of "poor adherence."

Fu Quan, Partner at Longma Peak Venture CapitalHe has provided an evaluation framework from an investment perspective. He believes this is a multi-billion-dollar “golden track” defined by substantial demand, active supply, and global policy support. The core of the evaluation lies in examining three aspects: sustained high market growth rates, a continuously improving payment environment, and most critically, the alignment between products and genuine clinical needs—specifically, whether they can address key pain points of existing therapies (such as GLP-1 agonists), including muscle loss and weight rebound after discontinuation. Therefore, the ultimate investment logic is to identify those that canEnterprises that leverage truly differentiated value to penetrate high-growth segments and address core clinical pain points。

Host, Bi Cheng, Partner at Wenzhou InvestmentThe summary highlights that the explosive growth in this sector is driven by three fundamental factors: stepwise iterations in therapeutic efficacy (with multi-target drugs approaching the effectiveness of surgery), a fundamental restructuring of product attributes (shifting from consumer choices to essential treatments for chronic diseases), and the continuous expansion of indications (extending from weight loss to multi-organ protection involving the heart, liver, and kidneys). These three factors collectively not only ignite current market enthusiasm but also fundamentally reshape the industry’s long-term growth potential and competitive landscape.

As competition in the weight loss sector expands from a single dimension of weight reduction magnitude to a comprehensive consideration of long-term metabolic health, the logic of R&D and the methods for building competitive moats are undergoing fundamental changes. Pharmaceutical companies, medical device manufacturers, and investors are all seeking differentiated paths amidst this transformation.

Drug Development Is Evolving from “Reducing Food Intake” to “Optimizing Metabolism”Han Dong pointed out that, in the face of pain points associated with GLP-1 drugs such as weight rebound after discontinuation and muscle loss, R&D efforts need to shift from pursuing “rapid weight loss” to ensuring “sustainable results and better health.” HighTide has chosen to bypass the mainstream GLP-1 pathway, instead developing mitochondrial uncouplers designed to “increase energy expenditure.” This approach aims to achieve precise fat burning while preserving muscle mass and providing liver protection, and it can synergize with GLP-1 therapies. In doing so, HighTide seeks to establish differentiated competitive barriers in the emerging arena of personalized, long-term health management.

Medical Device R&D Should Shift from “Single-Use Operations” to “Full-Cycle Health Stewardship”Chen Linfeng explained that Tangji Medical’s gastric bypass stent system serves as the “switch” to restart comprehensive management of metabolic diseases, while actual weight loss quality or metabolic improvement outcomes still rely on the integrated digital model of “hardware + software + services” built by Jixiang Health’s self-developed “Obesity Indicator Data Management Software” (i.e., DIx). The health management platform provides personalized health guidance, thereby deeply embedding into patients’ lives and enhancing adherence, thus forming strong user stickiness and a brand moat.

When evaluating targets, capital places greater emphasis on looking through the data to assess the alignment with “genuine demand.”Fu Quan shared that the primary consideration is the team’s systemic understanding of metabolic diseases and their ability to strategize around clinical pain points; secondly, whether preclinical data demonstrate differentiated advantages beyond weight loss; and finally, the assessment of top-tier clinical collaboration and operational capabilities. Furthermore, to mitigate risk, investors explicitly exclude “follower” projects lacking substantive innovation and those led by teams with limited clinical experience.

For pharmaceutical companies, medical device manufacturers, and investors alike, R&D competition in the weight-loss sector has entered a “deep-water zone.” The decisive factor is no longer merely the ability to reduce body weight, but rather the capacity to deliver sustainable solutions that offer comprehensive health benefits through mechanistic innovation or ecosystem building, thereby cultivating hard-to-replicate data assets and service systems in the process.

As R&D in the weight-loss sector deepens and the market landscape evolves, the nature of transactions and collaborations is rapidly upgrading. Simple patent licensing and sales-based royalties are no longer sufficient to address current competition; forming strategic alliances with deep integration and shared resources has become the new trend.

Balancing Protection and Efficiency Is Key in Complex Drug Combination Development. Han Dong shared HighTide’s pragmatic strategy: clearly delineating responsibilities by phase in production quality control; adopting “"Minimum Necessary Authorization + Phased Performance"Strategy: The scope of authorization gradually expands with the cooperation stages, and the design of liabilities for breach of contract pursues reciprocity and fairness to maximize cooperation efficiency.

For medical device companies, the terms of collaboration themselves have become a lever for securing strategic financing.. Chen Linfeng pointed out that its core logic is“Integrating Resources, Embracing the Future”Tangji Medical is exploring various collaboration opportunities with leading healthcare groups beyond traditional purchase and sales partnerships, with the aim of transforming short-term commercial partners into long-term communities of shared interest.

Cross-sector, cross-cycle strategic cooperation is becoming the mainstream.Fu Quan has observed three potential models: industry giants acquiring pipelines to fill gaps in their own product portfolios; technology platform companies empowering multiple pharmaceutical firms; and synergistic acquisitions undertaken by enterprises to create “combination strategies” (such as “weight loss + liver protection”). Evaluating such collaborations requires a thorough assessment of synergistic risks across technological, clinical, and commercial dimensions. The key drivers of value growth lie in the ability to open up entirely new market scenarios and whether the transaction structure is precisely aligned with the critical nodes of value creation.

Host Bi Cheng further pointed out that companies possessing foundational platform technologies (such as novel delivery platforms) are commanding significant valuation premiums. Meanwhile, with cross-sector capital inflows into fields like medical aesthetics, enterprises may consider separating the “chronic disease” and “consumer” attributes of their product rights, thereby designing more targeted licensing models to capture value across different markets.

As the demand for weight loss extends into the broader realm of public health, the industry faces severe challenges such as off-label misuse and long-term safety concerns, even as it envisions exponential growth. This requires all stakeholders to demonstrate a sense of long-term responsibility that transcends commercial interests.

In the face of rapidly expanding market boundaries, attendees unanimously agreed that safeguarding the sustainable development of the industry requires enterprises and investors to jointly establish a line of defense for responsibility.

The primary responsibility of pharmaceutical companies lies in proactively extending the chain of evidence.Han Dong pointed out that registration clinical trials primarily serve the purpose of obtaining marketing approval. To address use in broader populations, it is essential to conduct post-marketing real-world studies to explore scientifically validated dosing regimens and treatment durations for “modest weight loss” needs, and to establish a long-term safety monitoring system. Meanwhile, rigorous patient and physician education, along with safeguarding product quality and market order, constitute an indispensable commercial responsibility.

Medical device companies play a key role in ecosystem integration and scientific popularization.Chen Linfeng emphasized that its value lies in addressing specific health issues, such as polycystic ovary syndrome (PCOS), through innovative products and promoting their inclusion in payment systems to achieve universal accessibility. As a connector, enterprises have the responsibility to integrate multidisciplinary resources—including nutrition and exercise—to provide scientific, one-stop solutions and guide rational, healthy consumption.

Investment institutions have incorporated management’s sense of responsibility into the core dimensions of their investment decision-making.Fu Quan candidly stated that capital must remain vigilant against the lure of short-term gains, guide portfolio companies toward self-discipline through post-investment management, prevent aggressive marketing to off-label populations, and actively encourage investment in long-term safety studies. In his view, a visionary management team that prioritizes reputation serves as the best barrier against systemic industry risks.

As GLP-1 analogs and similar devices continue to emerge, competing solely on technical parameters has become a red ocean. How can deeper barriers be built? The panelists outlined a roadmap for “higher-dimensional competition.”

Path 1: From “Pharmaceuticals” to a “Closed-Loop Service”Han Dong proposed that pharmaceutical companies could develop complementary digital tools (such as diet-tracking apps) or jointly launch nutritional meal replacements with partners, centered around their core products. This would create a “product + service” bundle to manage the entire weight-loss journey, thereby enhancing user experience and stickiness.

Path 2: From “Devices” to “Personalized Solutions”Chen Linfeng believes that future competition will be “solutions versus single products.” Tangji Medical is simultaneously building a three-dimensional product ecosystem that covers “diverse needs and all intervention stages.” From devices to services, and from prevention to management, Tangji Medical provides comprehensive, systematic solutions for metabolic diseases, deeply aligning the company’s interests with patients’ long-term health.

Path 3: From “Sales” to “Ecosystem Building”. Fu Quan summarized that the ultimate differentiation lies in building a “metabolic disease solution platform.” This requires enterprises to integrate the characteristics of serious medical care and consumer healthcare, constructing service capabilities that combine telemedicine, nutritional planning, and exercise guidance. Furthermore, through payment innovations (such as installment plans), omnichannel coverage, and in-depth data application, companies can complete their transformation from product providers to health partners.

The Roundtable Comes Full Circle: The “Surge” in the Weight Loss Arena Must Ultimately Lead to Tangible Long-Term Health Benefits for Patients. As the game of mere “weight numbers” comes to an end, the decisive factor will shift to a higher-dimensional contest—determining who can build a more scientific, comprehensive, and sustainable health ecosystem for users. This is not merely a business strategy but an inevitable path for this multi-billion-dollar sector to evolve from hype to maturity.

The Hundred-Billion-Yuan Weight Loss Market: The Surge Continues, but the Direction Has Shifted.